The North America Next-Generation Sequencing (NGS) Market is witnessing exponential growth driven by technological advancements, increasing adoption in clinical diagnostics, and supportive government initiatives. The market size was valued at USD 4,800 Million in 2025 and is expected to reach USD 13,500 Million at a CAGR of 9.9% from 2024 to 2035.
The economic impact of tariffs on "North America Next-Generation Sequencing Market".
Market Growth Drivers
Rising Adoption in Clinical Diagnostics: The increasing adoption of next-generation sequencing in clinical diagnostics is a significant driver for market growth. Companies such as Illumina, Inc. and Thermo Fisher Scientific are introducing advanced NGS platforms that enable precise diagnosis and treatment of various diseases, including cancer and rare genetic disorders. With the integration of NGS into clinical workflows, healthcare providers can offer personalized therapies, resulting in improved patient outcomes. Furthermore, the decreasing cost of sequencing makes these technologies more accessible to a broader patient population, further driving market expansion.
Growing R&D Investments and Partnerships: Major market players are heavily investing in research and development to innovate new sequencing platforms and expand their service offerings. For instance, Pacific Biosciences has increased its R&D expenditure and formed strategic collaborations with biotechnology firms to accelerate the development of highly accurate and scalable NGS platforms. These investments not only enhance technological capabilities but also contribute to the development of novel sequencing applications, fostering market growth in North America.
Market Trends
Integration of Artificial Intelligence and Automation: The integration of artificial intelligence (AI) and automation in genomic data analysis is revolutionizing the NGS market. Leading companies like Roche and Illumina are deploying AI-based platforms to streamline sequencing workflows and improve data accuracy. Automation reduces human error and turnaround time, which is critical in clinical and research settings. AI-powered tools are also facilitating the interpretation of large-scale genomic data, enhancing the efficiency of personalized medicine and population health studies.
Expansion of NGS in Non-Invasive Prenatal Testing and Oncology: The use of NGS in non-invasive prenatal testing (NIPT) and oncology applications is rapidly expanding. Companies such as Guardant Health and Invitae are offering NGS-based liquid biopsy solutions for early cancer detection and monitoring. The ability to detect genetic mutations and chromosomal abnormalities in a non-invasive manner is driving demand among healthcare providers and patients alike. This trend is expected to further fuel market growth as NGS becomes an essential tool in preventive healthcare and early diagnosis.
Market Opportunities
Emergence of Personalized Medicine: The shift towards personalized medicine presents significant opportunities for NGS vendors. As precision medicine gains traction, demand for high-throughput sequencing technologies that provide comprehensive genetic profiling is increasing. Companies like Illumina are poised to benefit by developing custom NGS panels for tailored therapeutic strategies.
Expansion into Emerging Application Areas: Expanding NGS into new application areas such as microbiome sequencing, infectious disease surveillance, and pharmacogenomics offers lucrative growth potential. Firms including Thermo Fisher Scientific are launching innovative solutions to capture market share within these growing segments, addressing unmet needs and strengthening their foothold in North America.
North America Next-Generation Sequencing Market Revenue (USD Million), 2020-2035
The North America NGS market has exhibited steady revenue growth from 2020 to 2035. Beginning at USD 2,400 Million in 2020, the market grew consistently, reaching USD 4,800 Million in 2025 and is projected to hit USD 13,500 Million by 2035. Key contributing factors include the widespread adoption of NGS technologies in clinical and research domains, decreasing sequencing costs, strategic partnerships, and expanding reimbursement frameworks for genetic testing. Growth is further propelled by the introduction of innovative sequencing techniques and the rising utility of NGS in non-oncology and rare disease diagnostics. The chart highlights the sector's positive outlook, driven by ongoing advancements and expanding applications in precision medicine.
North America Next-Generation Sequencing Market by Region Share (%) - 2025
In 2025, the United States dominates the North America NGS market, accounting for 77% of the total market share, driven by well-established healthcare infrastructure, leading research facilities, and proactive regulatory support. Canada follows with 16%, benefitting from government initiatives, growing genomics research, and increased investment in healthcare technologies. Mexico holds 5% share, while the rest of North America (including countries such as Bermuda and Caribbean territories) collectively contribute 2%. The pie chart reflects the market's concentration in the US, but also highlights growth opportunities in adjacent regions as adoption rises and technology becomes more accessible.
Recent Developments in North America NGS Market (Last 6 Months)
Illumina, Inc. launched its NovaSeq X Plus sequencing system in January 2024, offering improved throughput, reduced sequencing cost per genome, and enhanced sustainability features. The company reported rapid adoption of the platform across major research institutions in North America, bolstering its competitive position and driving growth in high-throughput sequencing services.
In April 2024, Thermo Fisher Scientific announced an exclusive partnership with Mayo Clinic to develop and commercialize novel NGS panels for oncology and rare disease applications. This collaboration aims to combine Thermo Fisher’s advanced sequencing platforms with Mayo Clinic’s clinical and research expertise, accelerating the adoption of precision medicine and supporting earlier disease detection and better patient outcomes.
Pacific Biosciences secured FDA approval in March 2024 for its HiFi Long-Read Sequencing Solution in clinical diagnostic applications. This milestone enables PacBio to tap into the rapidly expanding clinical diagnostics segment, addressing unmet needs in genome-wide screening for structural variants in rare diseases, and supporting the growth of comprehensive genomic testing throughout North America.
Press Releases